Injectable Pricing & Rebate Tracker: Botox, Dysport, Jeuveau, Daxxify, Xeomin

Botox, Dysport, Jeuveau, Daxxify, and Xeomin all trade on per-unit cost, typically quoted as cost per unit in a standard vial (Botox and Dysport: 100 units; Jeuveau: 100 units; Daxxify: 110 units; Xeomin: 100 units). List pricing varies by distributor and direct-from-manufacturer agreements, but practices rarely pay list. Most large practices negotiate tiered pricing based on annual volume commitments: a practice committing 50,000 units annually of Botox may secure a per-unit cost 15–25% below a practice buying 10,000 units. Smaller practices and those without volume leverage typically pay 10–20% above the lowest negotiated tier. Direct-from-manufacturer programs (AbbVie's Allergan Aesthetics for Botox and Daxxify; Galderma for Dysport and Xeomin; Evolus for Jeuveau) often offer better per-unit pricing than group purchasing organizations (GPOs) or wholesalers, but require minimum order volumes and longer payment terms. Verify your current per-unit cost by dividing your last three invoices' total spend by total units purchased; practices often discover they are paying 8–12% more than their stated tier due to shipping, restocking fees, or expired rebate eligibility.

Allē is Allergan Aesthetics' loyalty platform for Botox, Daxxify, and Juvéderm fillers. The program offers tiered rebates based on annual spend: practices spending $50K–$100K annually may earn 2–3% rebate; $100K–$250K may earn 4–6%; $250K+ may earn 6–8% or higher. Rebates are typically paid quarterly or annually as account credits or checks. Allē also bundles promotional pricing on new launches (e.g., Daxxify at launch, Skinvive by Juvéderm for neck lines) and exclusive early-access pricing. The program resets annually on a calendar or fiscal-year basis; practices must track their cumulative spend to anticipate tier advancement and plan Q4 purchasing accordingly. Allē membership is free but requires enrollment through your Allergan Aesthetics sales rep or online portal. A critical detail: rebates are often contingent on meeting minimum order frequency (e.g., at least one order per quarter) and may be forfeited if you switch to a competitor mid-year. Model your rebate by calculating your expected annual toxin spend, identifying your tier, and subtracting the rebate percentage from your per-unit cost.

Galderma's Aspire program covers Dysport, Xeomin, and Restylane fillers. Aspire operates on a volume-acceleration model: practices earn rebates that increase as cumulative annual spend rises. For example, a practice might earn 1% rebate on the first $50K spent, 3% on the next $50K, and 5% on spend above $100K—meaning the marginal rebate on units purchased late in the year is higher than early purchases. This incentivizes front-loading purchases or maintaining consistent volume to hit higher tiers. Aspire also offers loyalty bonuses (flat cash rewards for hitting annual targets) and promotional pricing on specific products. Like Allē, Aspire requires enrollment and tracks spend on a calendar-year basis. Practices using both Dysport and Xeomin can aggregate spend across both products to reach higher tiers faster. A practice buying 30,000 units of Dysport and 10,000 units of Xeomin annually may hit a higher rebate tier than one buying only Dysport. Confirm your Aspire tier and rebate schedule with your Galderma rep; the structure can vary by region and sales territory.

Evolus Rewards is Evolus' loyalty program for Jeuveau (prabotulinumtoxinA), the company's neurotoxin competitor. Evolus Rewards offers tiered rebates and volume bonuses similar to Allē and Aspire, typically ranging from 2–7% depending on annual spend. Evolus has historically positioned Jeuveau as a price-competitive alternative to Botox and Dysport, often offering aggressive introductory pricing and rebates to practices switching from competitors. The program includes quarterly rebate payouts and promotional pricing on new indications (e.g., Jeuveau for crow's feet). Evolus' smaller market share means fewer practices are enrolled, but the program is transparent and easy to track. A key advantage: Evolus often bundles Jeuveau rebates with pricing on Evolus' energy devices (e.g., Morpheus8), creating cross-category incentives. If your practice uses Morpheus8 or other Evolus devices, you may negotiate combined rebate structures. Verify your Evolus Rewards tier and ensure you are capturing all promotional pricing; Evolus sales reps actively manage tier advancement and may proactively offer higher rebates to retain volume.

True landed cost = (invoice price per unit) − (rebate per unit) + (freight, storage, and waste allocation per unit). Example: Botox at $12.50 per unit on invoice, 5% annual rebate = $11.88 per unit; add $0.15 for freight and 2% waste = $12.03 true cost. If you inject at an average price of $15 per unit to patients, your gross margin per unit is $2.97, or 19.8%. At 50 injections per week (2,600 per year), that is $7,722 annual gross margin on toxin alone—before labor, overhead, and device costs. Practices with higher patient volume, premium pricing, or lower acquisition costs can achieve 25–30% gross margins on toxin. Practices with low volume or high acquisition costs may see margins below 15%, which is unsustainable. Model your breakeven by calculating: (annual fixed costs for injector labor + equipment depreciation) ÷ (gross margin per unit). A practice with $150K annual injector cost and $3 per-unit margin needs 50,000 units annually to break even on toxin alone. Use this framework to assess whether your current rebate tier and per-unit cost are competitive; if your true landed cost is above $13 per unit of Botox, you are likely overpaying relative to market.

Rebates are not immediate; they accrue quarterly or annually and are paid 30–90 days after the close of the period. This creates cash-flow timing risk: a practice may purchase $100K of toxin in Q4 expecting a $5K rebate in Q1, but the rebate may be delayed or reduced if the manufacturer audits your account for compliance (e.g., verifying you are not diverting product to unauthorized resellers). Manufacturers reserve the right to claw back rebates if you violate program terms (e.g., switching to a competitor mid-year, failing to meet minimum order frequency, or breaching pricing agreements). Rebate programs also change annually; Allergan Aesthetics, Galderma, and Evolus may adjust tier thresholds, rebate percentages, or eligibility criteria each January. A practice enrolled in Allē at 6% rebate in 2025 may find the program restructured in 2026 with lower rebates and higher spend thresholds. Stay informed by reviewing your annual program agreement and attending manufacturer webinars or sales calls in Q4 to understand upcoming changes. Document all rebate accruals in your accounting system; do not rely on manufacturer statements alone.